Liquidia Corporation settled with United Therapeutics, keeping the rights to market YUTREPIA for pulmonary arterial hypertension (PAH) but losing some commercial potential in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Despite this limitation, Liquidia can still sell YUTREPIA to existing PH-ILD patients and PAH patients, allowing continued revenue generation. The company also has another drug, L606, in development for PH-ILD, which could expand their market if trials and regulatory approvals succeed. Overall, Liquidia's long-term prospects remain positive due to ongoing opportunities with YUTREPIA and L606.
Liquidia Corporation's stock is trading at USD 57.41 on Pluang as of Nov 14, 2026 21:31 WIB, down 1.22% for the day. Despite the recent settlement limiting some commercial potential, the company's market cap stands at $5.17 billion with a high volume of 1,870,344 shares traded. The platform shows a strong sell sentiment with 94% of orders to sell, reflecting cautious investor behavior amid ongoing developments with YUTREPIA and L606.
